What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT04436978
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Registry
-
NCT04436978 -
2022-001298-30
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT04436978. Randomized; single masking; primary purpose prevention. Start 2023-01-11 (actual); primary completion 2027-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
- Acronym
- WOEST-3
- Condition
- Acute Coronary Syndrome
- Condition
- Myocardial Infarction
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Condition
- NSTEMI - Non-ST Segment Elevation MI
- Condition
- Bleeding
- Condition
- Stroke
- Condition
- Stent Thrombosis
- Condition
- Embolism
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- 30-day DAPT
- Intervention (Drug)
- Guideline-directed therapy
- Lead sponsor
- St. Antonius Hospital
- Collaborator
- Daiichi Sankyo
Record details
- Record id
cardio:ct-nct04436978- Content hash
1a3ea5b26c686a46ce65a28e80e75820640345ce567a9342aa2f5992bbdf8e3e